[1]
|
Ye, L., Lou, Y., Lu, L. and Fan, X. (2019) Mesothelin-Targeted Second Generation CAR-T Cells Inhibit Growth of Mesothelin-Expressing Tumors in Vivo. Experimental and Therapeutic Medicine, 17, 739-747.
https://doi.org/10.3892/etm.2018.7015
|
[2]
|
Sullivan, R., Alatise, O.I. anderson, B.O., et al. (2015) Global Cancer Surgery: Delivering Safe, Affordable, and Timely Cancer Surgery. The Lancet Oncology, 16, 1193-224. https://doi.org/10.1016/S1470-2045(15)00223-5
|
[3]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2016) Cancer Statistics, 2016. CA: A Cancer Journal for Clinicians, 66, 7-30.
https://doi.org/10.3322/caac.21332
|
[4]
|
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., et al. (2018) Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 378, 2078-2092.
https://doi.org/10.1056/NEJMoa1801005
|
[5]
|
罗添乐, 罗斌, 姚嘉良, 田建辉. 肺癌免疫治疗的临床研究进展[J]. 肿瘤学杂志, 2021, 27(1): 74-79.
|
[6]
|
Gross, G., Waks, T. and Eshhar, Z. (1989) Expression of Immunoglobulin-T-Cell Receptor Chimeric Molecules as Functional Receptors with Antibody-Type Specificity. Proceedings of the National Academy of Sciences of the United States of America, 86, 10024-10028. https://doi.org/10.1073/pnas.86.24.10024
|
[7]
|
刘睿, 李亚荣. CAR-T在晚期肺癌治疗中的研究进展[J]. 中国免疫学杂志, 2018, 34(12): 1907-1911.
|
[8]
|
Liu, Y. and He, Y. (2021) A Narrative Review of Chimeric Antigen Receptor-T (CAR-T) Cell Therapy for Lung Cancer. Annals of Translational Medicine, 9, 808. https://doi.org/10.21037/atm-20-5419
|
[9]
|
Kiesgen, S., Chicaybam, L., Chintala, N.K. and Adusumilli, P.S. (2018) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies. Journal of Thoracic Oncology, 13, 16-26.
https://doi.org/10.1016/j.jtho.2017.10.001
|
[10]
|
Greenhalgh, J., Dwan, K., Boland, A., et al. (2016) First-Line Treatment of Advanced Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Squamous Non-Small Cell Lung Cancer. Cochrane Database of Systematic Reviews, No. 5, CD010383. https://doi.org/10.1002/14651858.CD010383.pub2
|
[11]
|
Qu, J., Mei, Q., Chen, L. and Zhou, J. (2021) Chimeric Antigen Receptor (CAR)-T-Cell Therapy in Non-Small-Cell Lung Cancer (NSCLC): Current Status and Future Perspectives. Cancer Immunology, Immunotherapy, 70, 619-631.
https://doi.org/10.1007/s00262-020-02735-0
|
[12]
|
Wang, J., Chen, J., Guo, Y., Wang, B. and Chu, H. (2017) Strategies Targeting Angiogenesis in Advanced Non-Small Cell Lung Cancer. Oncotarget, 8, 53854-53872. https://doi.org/10.18632/oncotarget.17957
|
[13]
|
Li, H., Huang, Y., Jiang, D.Q., et al. (2018) Antitumor Activity of EGFR-Specific CAR T Cells against Non-Small-Cell Lung Cancer Cells in Vitro and in Mice. Cell Death & Disease, 9, 177. https://doi.org/10.1038/s41419-017-0238-6
|
[14]
|
Pastan, I. and Hassan, R. (2014) Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy. Cancer Research, 74, 2907-2912. https://doi.org/10.1158/0008-5472.CAN-14-0337
|
[15]
|
Kawaguchi, T., Sho, M., Tojo, T., et al. (2010) Clinical Significance of Prostate Stem Cell Antigen Expression in Non-Small Cell Lung Cancer. Japanese Journal of Clinical Oncology, 40, 319-326.
https://doi.org/10.1093/jjco/hyp181
|
[16]
|
Situ, D., Wang, J., Ma, Y., et al. (2011) Expression and Prognostic Relevance of MUC1 in Stage IB Non-Small Cell Lung Cancer. Medical Oncology, 28, S596-S604. https://doi.org/10.1007/s12032-010-9752-4
|
[17]
|
Wei, X., Lai, Y., Li, J., et al. (2017) PSCA and MUC1 in Non-Small-Cell Lung Cancer as Targets of Chimeric Antigen Receptor T Cells. Oncoimmunology, 6, e1284722. https://doi.org/10.1080/2162402X.2017.1284722
|
[18]
|
覃远静, 王雪梅, 童燕娜, 等. 肿瘤血清标志物水平升高与非小细胞肺癌患者发生脑转移的关系[J]. 中华保健医学杂志, 2020, 22(2): 194-196.
|
[19]
|
翟素平, 黄秀红, 马昕炜. 血清CEA、CA125水平在靶向药物治疗非小细胞肺癌的疗效预测中的价值[J]. 实验与检验医学, 2021(39): 697-699+709.
|
[20]
|
Suarez, E.R., Chang de, K., Sun, J., et al. (2016) Chimeric Antigen Receptor T Cells Secreting Anti-PD-L1 Antibodies More Effectively Regress Renal Cell Carcinoma in a Humanized Mouse Model. Oncotarget, 7, 34341-34355.
https://doi.org/10.18632/oncotarget.9114
|
[21]
|
Liu, M., Wang, X., Li, W., et al. (2020) Targeting PD-L1 in Non-Small Cell Lung Cancer Using CAR T Cells. Oncogenesis, 9, 72. https://doi.org/10.1038/s41389-020-00257-z
|
[22]
|
Berger, C., Sommermeyer, D., Hudecek, M., et al. (2015) Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells. Cancer Immunology Research, 3, 206-216.
https://doi.org/10.1158/2326-6066.CIR-14-0163
|
[23]
|
Wallstabe, L., Göttlich, C., Nelke, L.C., et al. (2019) ROR1-CAR T Cells Are Effective against Lung and Breast Cancer in Advanced Microphysiologic 3D Tumor Models. JCI Insight, 4, e126345.
https://doi.org/10.1172/jci.insight.126345
|
[24]
|
Hirsh, V. (2015) Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. BioDrugs, 29, 167-183. https://doi.org/10.1007/s40259-015-0130-9
|
[25]
|
Zhao, Y., Wang, Q.J., Yang, S., et al. (2009) A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity. The Journal of Immunology, 183, 5563-5574. https://doi.org/10.4049/jimmunol.0900447
|
[26]
|
Zheng, X., Cheng, M., Fu, B., et al. (2015) Targeting LUNX Inhibits Non-Small Cell Lung Cancer Growth and Metastasis. Cancer Research, 75, 1080-1090. https://doi.org/10.1158/0008-5472.CAN-14-1831
|
[27]
|
Hu, Z., Zheng, X., Jiao, D., et al. (2020) LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer. Molecular Therapy—Oncolytics, 17, 361-370. https://doi.org/10.1016/j.omto.2020.04.008
|